NCT02226328

Brief Summary

Flexible bronchoscopy almost always requires sedation to be successful. In order to increase the availability of propofol for sedation, non-anaesthesiologist administered propofol sedation has been suggested as an alternative to traditional midazolam/opioid sedation or the general anaesthesia provided by anaesthesiologists. Hypothesis: Patients undergoing flexible bronchoscopy prefers non-anaesthesiologist administered sedation with propofol as opposed to non-anaesthesiologist administered sedation with midazolam and fentanyl. Propofol sedation is as safe as midazolam and fentanyl sedation.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
128

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Nov 2014

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 19, 2014

Completed
8 days until next milestone

First Posted

Study publicly available on registry

August 27, 2014

Completed
2 months until next milestone

Study Start

First participant enrolled

November 1, 2014

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2015

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2016

Completed
Last Updated

June 30, 2015

Status Verified

June 1, 2015

Enrollment Period

1.1 years

First QC Date

August 19, 2014

Last Update Submit

June 29, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Satisfaction with sedation

    The average duration of bronchoscopy is estimated to 20 minutes. A validated satisfaction questionnaire will be filled by the patient at discharge from the recovery room, on average 30 minutes after completed procedure. Readiness for discharge will be assessed using an Aldrete score.

    At discharge, on average 30 minutes after procedure termination.

Secondary Outcomes (1)

  • Number of adverse events as a surrogate marker of safety.

    During procedure. On average 20 minutes.

Other Outcomes (1)

  • Patient comfort

    Per-operatively, on average 20 minutes

Study Arms (2)

Propofol sedation

EXPERIMENTAL

Refract bolus propofol sedation as monotherapy administered by a sedation-trained nurse endoscopist. Induction with 10-60 mg bolus, repeated every 45-60 sec. until moderate sedation. Maintenance with 10-20 mg of propofol in case of discomfort.

Drug: Propofol sedation

Midazolam and Fentanyl sedation

ACTIVE COMPARATOR

1-2 mg of Midazolam with 0.025-0.05 mg of fentanyl for induction 10 prior to procedure initiation. Maintenance with 1 mg Midazolam in case of discomfort.

Drug: Midazolam and Fentanyl sedation

Interventions

Also known as: ATC code: N01AX10, CAS no: 2078-54-8
Propofol sedation
Also known as: Midazolam:, ATC code: N05CD08, CAS no: 59467-70-8, Fentanyl:, ATC code: N01AH01, CAS no: 437-38-7
Midazolam and Fentanyl sedation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Elective flexible bronchoscopy.
  • Willing to be randomised
  • Provide written informed consent

You may not qualify if:

  • Allergy to contents administered
  • pregnant or nursing
  • \<18 years of age
  • Not able to complete questionnaire
  • Acute condition
  • severe COPD
  • \> ASA II
  • Sleep apnea
  • Risk of aspiration
  • Previously difficulty with anesthesia
  • Difficult airway

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gentofte Hospital

Hellerup, 2900, Denmark

RECRUITING

MeSH Terms

Conditions

Personal Satisfaction

Interventions

MidazolamFentanyl

Condition Hierarchy (Ancestors)

Behavior

Intervention Hierarchy (Ancestors)

BenzodiazepinesBenzazepinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsPiperidinesHeterocyclic Compounds, 1-Ring

Study Officials

  • Paul F Clementsen, Professor

    University of Copenhagen at Gentofte Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Paul F Clementsen, Professor

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 19, 2014

First Posted

August 27, 2014

Study Start

November 1, 2014

Primary Completion

December 1, 2015

Study Completion

April 1, 2016

Last Updated

June 30, 2015

Record last verified: 2015-06

Locations